Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
EMA Reviewing Cardiovascular & Cancer Risk From Five Janus Kinase Inhibitors
Feb 14 2022
•
By
Neena Brizmohun
A review into the safety of five JAK inhibitors has started • Source: Alamy
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Drug Safety
More from Pink Sheet